Anthem Biosciences Ltd
Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the co… Read more
Anthem Biosciences Ltd (ANTHEM) - Net Assets
Latest net assets as of September 2025: ₹27.53 Billion INR
Based on the latest financial reports, Anthem Biosciences Ltd (ANTHEM) has net assets worth ₹27.53 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹32.84 Billion) and total liabilities (₹5.32 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹27.53 Billion |
| % of Total Assets | 83.81% |
| Annual Growth Rate | 21.15% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 7.78 |
Anthem Biosciences Ltd - Net Assets Trend (2022–2025)
This chart illustrates how Anthem Biosciences Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Anthem Biosciences Ltd (2022–2025)
The table below shows the annual net assets of Anthem Biosciences Ltd from 2022 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹24.10 Billion | +25.21% |
| 2024-03-31 | ₹19.25 Billion | +10.57% |
| 2023-03-31 | ₹17.41 Billion | +28.46% |
| 2022-03-31 | ₹13.55 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Anthem Biosciences Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 97.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹19.23 Billion | 79.78% |
| Common Stock | ₹1.12 Billion | 4.64% |
| Other Components | ₹3.75 Billion | 15.58% |
| Total Equity | ₹24.10 Billion | 100.00% |
Anthem Biosciences Ltd Competitors by Market Cap
The table below lists competitors of Anthem Biosciences Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Generic Sweden publ AB
ST:GENI
|
$17.47 Million |
|
Acer Gadget Inc
TW:2432
|
$17.47 Million |
|
YCQH Agricultural Technology Co. Ltd.
PINK:YCQH
|
$17.48 Million |
|
James Maritime Holdings Inc
PINK:JMTM
|
$17.48 Million |
|
Zivo Bioscience Inc
NASDAQ:ZIVO
|
$17.46 Million |
|
MR. BRICOLAGE INH. EO 32
F:4OL
|
$17.46 Million |
|
Provenance Gold Corp
OTCQB:PVGDF
|
$17.46 Million |
|
Energía Innovación y Desarrollo Fotovoltaico S.A.
MC:EIDF
|
$17.45 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Anthem Biosciences Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 19,246,550,000 to 24,098,640,000, a change of 4,852,090,000 (25.2%).
- Net income of 4,512,590,000 contributed positively to equity growth.
- Other factors increased equity by 339,500,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹4.51 Billion | +18.73% |
| Other Changes | ₹339.50 Million | +1.41% |
| Total Change | ₹- | 25.21% |
Book Value vs Market Value Analysis
This analysis compares Anthem Biosciences Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 15.02x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 26.71x to 15.02x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-03-31 | ₹24.13 | ₹644.40 | x |
| 2023-03-31 | ₹30.99 | ₹644.40 | x |
| 2024-03-31 | ₹34.27 | ₹644.40 | x |
| 2025-03-31 | ₹42.91 | ₹644.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Anthem Biosciences Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.73%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 24.46%
- • Asset Turnover: 0.66x
- • Equity Multiplier: 1.17x
- Recent ROE (18.73%) is below the historical average (22.47%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 29.93% | 32.94% | 0.76x | 1.19x | ₹2.70 Billion |
| 2023 | 22.13% | 36.44% | 0.52x | 1.16x | ₹2.11 Billion |
| 2024 | 19.08% | 25.88% | 0.59x | 1.25x | ₹1.75 Billion |
| 2025 | 18.73% | 24.46% | 0.66x | 1.17x | ₹2.10 Billion |
Industry Comparison
This section compares Anthem Biosciences Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $14,394,154,434
- Average return on equity (ROE) among peers: -9.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Anthem Biosciences Ltd (ANTHEM) | ₹27.53 Billion | 29.93% | 0.19x | $17.47 Million |
| BALAXI PHARMACEUTICALS LIMITED (BALAXI) | $15.55 Million | -49.65% | 0.08x | $11.03 Million |
| Biocon Limited (BIOCON) | $14.77 Billion | 31.41% | 0.41x | $2.58 Billion |
| Blue Jet Healthcare Limited (BLUEJET) | $8.45 Billion | 19.37% | 0.25x | $136.39 Million |
| Concord Biotech Limited (CONCORDBIO) | $18.13 Billion | 20.50% | 0.12x | $355.66 Million |
| Dishman Carbogen Amcis Limited (DCAL) | $9.29 Billion | 6.11% | 1.42x | $104.90 Million |
| Haleos Labs Limited (HALEOSLABS) | $1.06 Billion | 16.78% | 1.56x | $134.43K |
| Lyka Labs Limited (LYKALABS) | $582.36 Million | -29.66% | 3.04x | $8.77 Million |
| ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE) | $75.29 Billion | 0.00% | 0.00x | $1.21 Billion |
| Panacea Biotec Limited (PANACEABIO) | $1.96 Billion | -99.24% | 6.10x | $56.39 Million |